Factors affecting response of chemotherapy in women with ovarian cancer

被引：0

作者：

Lubin, J. ^{[1
]}

Markowska, A. ^{[2
]}

Knapp, P. ^{[3
]}

机构：

[1] Clin Oncol Poznan, Dept Gynecol, Poznan, Poland

[2] Inst Gynecol & Obstet, Poznan, Poland

[3] Univ Hosp Bialystok, Dept Gynecol, Bialystok, Poland

来源：

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2012年 / 33卷 / 06期

关键词：

Ovarian cancer; Chemotherapy; Factors affecting chemotherapy; MULTIDRUG-RESISTANCE GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PRODUCT P-GLYCOPROTEIN; PACLITAXEL RESISTANCE; PROTEIN LRP; E-CADHERIN; EXPRESSION; CLUSTERIN; MDR1; CYCLOOXYGENASE-2;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy plays an important role in the treatment of ovarian cancer. Patients' response to chemotherapy is determined by a variety of acknowledged factors, but one might expect that many of them are yet to be described. The aim of this paper was to present the most essential yet still to be generally assessed in clinical practice, factors, which include: E-cadhedrin, hypoxia inducible factor alpha, survivin, COX-2, clusterin, BRCA1 protein, TP53 protein, YY1 protein, multidrug resistance protein, and interleukin-8.

引用

下载

页码：644 / 647

页数：4

共 50 条

[31] FACTORS INFLUENCING OVARIAN CANCER SURVIVAL AFTER CHEMOTHERAPY
WEBB, MJ
MALKASIAN, GD
JORGENSEN, EO
OBSTETRICS AND GYNECOLOGY, 1974, 44 (04): : 564 - 570
[32] Factors affecting recurrence rates in women with borderline ovarian tumors.
Scanlon, Lauren
Goldberg, Gary L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Hereditary ovarian cancer: biology, response to chemotherapy and prognosis
Safra, Tamar
WOMENS HEALTH, 2009, 5 (05) : 543 - 553
[34] MicroRNAs that underlie response to salvage chemotherapy in ovarian cancer
Boren, T. P.
Cui, S.
Chan, G.
Dressman, H.
Lancaster, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[35] CA 125 as predictor of response to chemotherapy in ovarian cancer
Verheijen, RHM
Van Kamp, GJ
Kenemans, P
7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 21 - 27
[36] Copper transport system and response to ovarian cancer chemotherapy
Karolina Tecza
Jolanta Pamula-Pilat
Zofia Kolosza
Ewa Grzybowska
Hereditary Cancer in Clinical Practice, 13 (Suppl 2)
[37] Is neoadjuvant chemotherapy feasible prior to intraperitoneal chemotherapy in women with advanced ovarian cancer?
Barnett, G.
Rogers, A.
Robinson, W.
GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 366 - 366
[38] Factors affecting ovarian cancer treatment in the octogenarian patient population
Rasool, N.
Buekers, T. E.
Hanna, R. K.
Munkarah, A. R.
Alford, S. Hensley
GYNECOLOGIC ONCOLOGY, 2015, 137 : 187 - 187
[39] Changes in Depression and Sleep Quality and Associated Factors in Women Receiving Chemotherapy for Ovarian Cancer An Observational Study
Wu, Hui-Ju
Chuang, Chi-Mu
Chien, Ching-Hui
Wang, Tsae-Jyy
Liang, Shu-Yuan
CANCER NURSING, 2022, 45 (04) : 271 - 279
[40] Laparoscopic ovarian drilling in women with polycystic ovarian syndrome: a reappraisal of the factors affecting the clinical outcome
Amer, S. A. K.
Li, T. C.
Ledger, W. L.
HUMAN REPRODUCTION, 2003, 18 : 175 - 176

← 1 2 3 4 5 →